Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inimitable Ablexis Delivers Mice To Partners, Multiples To Investors

This article was originally published in Start Up

Executive Summary

Antibody platform play Ablexis has successfully built its technology, fulfilled a commitment to its pharmaceutical partners, triumphed in a lawsuit brought by one of biotech’s big boys, and lined the pockets of its investors. Surprisingly, it has no imitators.

You may also be interested in...



GSK’s Venture Deal With Avalon Yields Three Start-Ups In Two Years

Silarus Therapeutics and Thyritope Biosciences are the latest two companies to be launched and financed by GlaxoSmithKline and partner Avalon Ventures. During Informa’s Pharmaceutical Strategy Conference, GSK’s Lon Cardon talks about how the partnership with Avalon is helping the Big Pharma access academic science.

Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns

As executives and investors scramble to find business models that more closely link investment and return, a handful of technology firms have alit on variations of a capital-efficient strategy: let someone else do the development dirty work.

Ablexis' Pharmaceutical Consortium

Ablexis LLC's October 2010 consortium-based alliance with Pfizer Inc. and four other undisclosed "Top 15" drugmakers represents an important new variation in platform-technology deal-making.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel